This page summarizes the latest approvals issued by the U.S. Food and Drug Administration (FDA). The list includes newly approved therapies as well as additional indications for ex...
ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...